https://www.deciphera.com/ 2025-09-17T16:28:04-04:00 daily 1.0 https://www.deciphera.com/join-us/open-positions 2021-05-28T16:32:19-04:00 0.5 https://www.deciphera.com/discovery-platform 2024-06-06T11:56:15-04:00 0.5 https://www.deciphera.com/discovery-platform/switch-control-kinase-inhibitor-platform 2020-12-17T16:33:03-05:00 0.5 https://www.deciphera.com/discovery-platform/potential-impact 2020-12-05T11:22:15-05:00 0.5 https://www.deciphera.com/pipeline/expanded-access 2025-09-23T12:53:34-04:00 0.5 https://www.deciphera.com/our-medicine 2025-02-27T14:23:50-05:00 0.5 https://www.deciphera.com/about 2024-11-14T15:06:23-05:00 0.5 https://www.deciphera.com/about/management 2026-03-17T15:16:03-04:00 0.5 https://www.deciphera.com/join-us 2025-05-20T11:54:03-04:00 0.5 https://www.deciphera.com/patients-caregivers 2025-02-14T15:52:06-05:00 0.5 https://www.deciphera.com/healthcare-professionals 2025-02-25T11:59:34-05:00 0.5 https://www.deciphera.com/clinical-studies 2025-02-14T15:49:04-05:00 0.5 https://www.deciphera.com/presentations-publications 2021-02-03T09:34:24-05:00 0.5 https://www.deciphera.com/contact-us 2026-03-04T16:09:51-05:00 0.5 https://www.deciphera.com/terms-use 2020-12-15T20:41:07-05:00 0.5 https://www.deciphera.com/web-accessibility-statement 2020-12-09T14:24:12-05:00 0.5 https://www.deciphera.com/privacy-policy 2025-05-06T10:10:25-04:00 0.5 https://www.deciphera.com/deciphera-policies 2025-03-11T13:47:13-04:00 0.5 https://www.deciphera.com/about/corporate-governance 2024-11-14T15:07:32-05:00 0.5 https://www.deciphera.com/compliance-hotline 2025-07-08T11:31:21-04:00 0.5 https://www.deciphera.com/news/ono-announces-results-tender-offer-acquire-deciphera-pharmaceuticals-and-completion 2024-06-11T14:44:03-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-announces-oral-presentation-results-motion-pivotal-phase-3-study 2024-06-03T13:52:18-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-be-acquired-ono-pharmaceutical-24-billion 2024-04-29T11:00:46-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-present-stifel-2024-virtual-targeted-oncology-forum 2024-04-09T11:00:23-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-participate-upcoming-investor-conferences 2024-02-27T12:00:37-05:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-announces-fourth-quarter-and-full-year-2023-financial-results 2024-02-06T12:00:41-05:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-announce-fourth-quarter-and-full-year-2023-financial-results-and 2024-02-01T21:52:23-05:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-present-guggenheim-healthcare-talks-6th-annual-biotechnology 2024-02-01T12:00:30-05:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-presents-long-term-follow-results-intrigue-phase-3-clinical-study 2024-01-18T16:13:20-05:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-announces-planned-2024-corporate-milestones-supporting-evolution 2024-01-08T12:00:16-05:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-announces-nature-medicine-publication-results-exploratory-ctdna 2024-01-05T12:04:28-05:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-present-42nd-annual-jp-morgan-healthcare-conference 2024-01-02T12:00:34-05:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-present-jmp-securities-hematology-and-oncology-summit 2023-11-29T12:00:29-05:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-participate-upcoming-investor-conferences-0 2023-11-07T12:00:22-05:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-announces-third-quarter-2023-financial-results 2023-10-30T11:30:30-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-announces-positive-top-line-results-motion-pivotal-phase-3-study 2023-10-30T11:00:31-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635c4 2023-09-15T21:00:19-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-0 2023-08-18T20:05:23-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-announces-second-quarter-2023-financial-results 2023-08-09T11:00:30-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-announces-retirement-daniel-l-flynn-phd-and-appointment-dashyant 2023-08-03T20:15:24-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-announce-second-quarter-2023-financial-results-and-host-conference 2023-08-02T11:00:36-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-present-data-intrigue-phase-3-study-qinlockr-ripretinib-and-trial 2023-05-25T21:00:21-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-participate-upcoming-investor-conferences-1 2023-05-23T11:00:43-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-present-jmp-securities-life-sciences-conference 2023-05-08T11:02:11-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-announces-first-quarter-2023-financial-results 2023-05-03T11:00:24-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-announce-first-quarter-2023-financial-results-and-host-conference 2023-04-26T11:00:29-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-present-stifel-virtual-targeted-oncology-days 2023-04-19T11:00:26-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-announces-qinlockr-included-nccn-guidelinesr-treatment-second-line 2023-03-14T21:54:54-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-announces-eight-presentations-highlighting-discovery-research 2023-03-14T21:32:36-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-announces-completion-enrollment-pivotal-phase-3-motion-study 2023-03-01T12:00:34-05:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-participate-upcoming-investor-conferences-2 2023-02-28T14:16:23-05:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-announces-fourth-quarter-and-full-year-2022-financial-results 2023-02-07T12:02:52-05:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-participate-upcoming-investor-conferences-3 2023-02-02T12:02:13-05:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-announce-fourth-quarter-and-full-year-2022-financial-results-and 2023-01-31T12:00:54-05:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-announces-closing-public-offering-common-stock-and-full-exercise 2023-01-24T21:02:10-05:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-presents-results-ctdna-analysis-intrigue-phase-3-clinical-study 2023-01-24T21:01:20-05:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-announces-pricing-public-offering-common-stock 2023-01-23T18:42:22-05:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-announces-proposed-public-offering-common-stock 2023-01-23T18:41:40-05:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-announces-planned-2023-corporate-milestones-support-continued 2023-01-23T18:41:13-05:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-announces-results-ctdna-analysis-intrigue-phase-3-clinical-study 2023-01-23T18:40:42-05:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-inc-present-41st-annual-jp-morgan-healthcare-conference 2023-01-23T18:40:12-05:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-inc-present-jmp-securities-hematology-and-oncology-summit 2023-01-23T18:39:39-05:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-inc-participate-upcoming-investor-conferences 2023-01-23T18:39:12-05:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-inc-announces-third-quarter-2022-financial-results 2023-01-23T18:37:57-05:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-inc-announce-third-quarter-2022-financial-results-and-host 2023-01-23T18:37:02-05:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-inc-presents-updated-phase-12-data-vimseltinib-tgct-european-society 2023-01-23T18:36:37-05:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-inc-presents-initial-phase-1-single-agent-dose-escalation-data-first 2023-01-23T18:34:47-05:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-inc-host-virtual-investor-event-featuring-key-opinion-leaders 2022-09-01T11:00:34-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-1 2022-08-19T20:05:11-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-inc-announces-publication-intrigue-phase-3-clinical-study-results 2022-08-10T20:20:18-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-inc-announces-second-quarter-2022-financial-results 2022-08-04T11:00:51-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-inc-announce-second-quarter-2022-financial-results-and-host 2022-07-28T11:00:20-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-2 2022-07-15T20:20:18-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-inc-appoints-kelley-dealhoy-chief-business-officer 2022-06-16T11:02:12-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-inc-participate-upcoming-investor-conferences-0 2022-06-02T11:00:30-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-inc-announces-first-quarter-2022-financial-results 2022-05-04T11:00:31-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-announce-first-quarter-2022-financial-results-and-host-conference 2022-05-02T12:00:15-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-announces-closing-public-offering-common-stock-and-pre-funded 2022-04-29T20:09:19-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-announces-pricing-public-offering-common-stock-and-pre-funded 2022-04-27T04:02:23-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-announces-proposed-public-offering-common-stock-and-pre-funded 2022-04-26T20:10:21-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-presents-preclinical-data-dcc-3116-program-aacr-annual-meeting 2022-04-12T19:50:26-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-inc-present-barclays-global-healthcare-conference 2022-03-09T12:02:41-05:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-inc-announces-fourth-quarter-and-full-year-2021-financial-results 2022-02-08T21:08:21-05:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-inc-present-upcoming-investor-conferences 2022-02-02T12:01:49-05:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-announce-fourth-quarter-and-full-year-2021-financial-results-and 2022-02-01T12:01:37-05:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-presents-results-intrigue-phase-3-clinical-study-american-society 2022-01-24T22:01:17-05:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-provides-corporate-update-and-highlights-key-2022-corporate 2022-01-10T12:02:55-05:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-inc-present-40th-annual-jp-morgan-healthcare-conference 2022-01-03T12:02:50-05:00 0.5 https://www.deciphera.com/news/deciphera-announces-approval-qinlockr-united-kingdom-treatment-fourth-line-gastrointestinal 2021-12-21T13:44:51-05:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-announces-restructuring-prioritize-clinical-development-programs-and 2021-11-30T13:31:04-05:00 0.5 https://www.deciphera.com/news/deciphera-receives-european-commission-approval-qinlockr-treatment-fourth-line 2021-11-22T12:01:18-05:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-announces-top-line-results-intrigue-phase-3-clinical-study 2021-11-05T11:01:30-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-inc-announces-third-quarter-2021-financial-results 2021-11-02T20:02:39-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-announce-third-quarter-2021-financial-results-and-host-conference 2021-10-26T11:02:16-04:00 0.5 https://www.deciphera.com/news/deciphera-announces-approval-qinlockr-switzerland-treatment-fourth-line-gastrointestinal 2021-10-12T11:01:03-04:00 0.5 https://www.deciphera.com/news/deciphera-presents-preclinical-data-dcc-3116-program-aacr-nci-eortc-international-conference 2021-10-07T13:02:24-04:00 0.5 https://www.deciphera.com/news/deciphera-announces-positive-chmp-opinion-qinlockr-treatment-fourth-line-gastrointestinal 2021-09-17T12:17:56-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-presents-new-clinical-study-results-across-pipeline-european-society 2021-09-17T11:01:01-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-host-virtual-investor-event-featuring-key-opinion-leaders-discuss 2021-09-10T11:01:02-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-inc-present-19th-annual-morgan-stanley-global-healthcare-conference 2021-09-02T11:01:22-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-inc-announces-second-quarter-2021-financial-results 2021-08-03T20:02:38-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-announce-second-quarter-2021-financial-results-and-host-conference 2021-07-27T11:01:06-04:00 0.5 https://www.deciphera.com/news/deciphera-announces-first-patient-treated-phase-1-study-dcc-3116-patients-advanced-or 2021-06-30T20:01:58-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-presents-data-qinlockr-and-rebastinib-programs-2021-american-society 2021-06-04T13:01:45-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-inc-present-upcoming-investor-conferences-0 2021-05-27T11:02:23-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-inc-announces-first-quarter-2021-financial-results 2021-05-04T20:23:33-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-announce-first-quarter-2021-financial-results-and-host-conference 2021-04-27T11:02:03-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-inc-present-barclays-global-healthcare-conference-0 2021-03-02T12:01:54-05:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-inc-present-svb-leerink-10th-annual-global-healthcare-conference 2021-02-18T12:01:01-05:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-inc-announces-fourth-quarter-and-full-year-2020-financial-results 2021-02-09T21:02:32-05:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-inc-present-guggenheim-healthcare-talks-2021-idea-forum-oncology-day 2021-02-04T12:01:25-05:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-announce-fourth-quarter-and-full-year-2020-financial-results-and 2021-02-02T12:01:54-05:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-provides-corporate-update-and-highlights-key-2021-corporate 2021-01-11T12:03:43-05:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-present-39th-annual-jp-morgan-healthcare-conference 2021-01-05T12:24:42-05:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-completes-target-enrollment-intrigue-phase-3-clinical-study-qinlockr 2020-11-30T12:00:52-05:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-inc-participate-piper-sandler-32nd-annual-virtual-healthcare 2020-11-24T21:01:58-05:00 0.5 https://www.deciphera.com/news/boston-globe-names-deciphera-top-place-work-2020 2020-11-23T12:01:11-05:00 0.5 https://www.deciphera.com/news/deciphera-presents-data-qinlockr-ripretinib-program-connective-tissue-oncology-society-ctos 2020-11-11T12:02:35-05:00 0.5 https://www.deciphera.com/news/deciphera-presents-updated-preliminary-data-dcc-3014-its-csf1r-inhibitor-program-tenosynovial 2020-11-11T12:00:44-05:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-inc-present-jefferies-virtual-london-healthcare-conference 2020-11-10T12:00:50-05:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-inc-announces-third-quarter-2020-financial-results 2020-11-05T21:02:19-05:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-inc-announce-third-quarter-2020-financial-results-and-host 2020-10-28T11:00:39-04:00 0.5 https://www.deciphera.com/news/deciphera-presents-data-qinlocktm-ripretinib-program-patients-gastrointestinal-stromal-tumor 2020-09-18T11:00:54-04:00 0.5 https://www.deciphera.com/news/deciphera-presents-data-rebastinib-its-tie2-inhibitor-program-european-society-medical 2020-09-17T11:01:07-04:00 0.5 https://www.deciphera.com/news/deciphera-announces-publication-qinlocktm-ripretinib-phase-1-study-results-patients 2020-08-17T20:30:49-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-inc-present-canaccord-genuity-40th-annual-growth-conference 2020-08-06T12:40:50-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-inc-announces-second-quarter-2020-financial-results 2020-08-04T20:06:20-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-inc-announce-second-quarter-2020-financial-results-and-host 2020-07-29T11:01:01-04:00 0.5 https://www.deciphera.com/news/china-nmpa-accepts-nda-submission-ripretinib-advanced-gastrointestinal-stromal-tumor 2020-07-20T21:32:51-04:00 0.5 https://www.deciphera.com/news/deciphera-announces-australian-therapeutic-goods-administrations-approval-qinlocktm-ripretinib 2020-07-14T11:00:55-04:00 0.5 https://www.deciphera.com/news/deciphera-announces-presentation-analysis-crossover-population-invictus-phase-3-study 2020-07-02T20:02:02-04:00 0.5 https://www.deciphera.com/news/deciphera-announces-health-canadas-authorization-qinlocktm-ripretinib-treatment-fourth-line 2020-06-22T11:01:09-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-present-jmp-securities-hematology-and-oncology-forum 2020-06-11T11:00:37-04:00 0.5 https://www.deciphera.com/news/deciphera-announces-publication-invictus-pivotal-phase-3-study-qinlocktm-ripretinib-lancet 2020-06-08T11:30:45-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-presents-preliminary-data-phase-1b2-study-rebastinib-combination 2020-05-29T12:05:47-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-announces-presentations-positive-patient-reported-outcomes-results 2020-06-15T15:28:15-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-present-jefferies-2020-healthcare-conference 2020-05-28T23:07:55-04:00 0.5 https://www.deciphera.com/news/fda-grants-full-approval-deciphera-pharmaceuticals-qinlocktm-ripretinib-treatment-fourth-line 2020-05-15T23:01:43-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-inc-announces-first-quarter-2020-financial-results 2020-05-05T20:01:55-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-inc-announce-first-quarter-2020-financial-results-and-host 2020-04-28T11:00:43-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-inc-announces-fourth-quarter-and-full-year-2019-financial-results 2020-03-09T20:01:48-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-inc-announce-fourth-quarter-and-full-year-2019-financial-results-and 2020-03-02T12:00:52-05:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-inc-present-9th-annual-svb-leerink-global-healthcare-conference 2020-02-20T12:00:52-05:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-announces-closing-public-offering-common-stock 2020-02-19T21:02:00-05:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-announces-pricing-public-offering-common-stock-0 2020-02-14T03:12:31-05:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-announces-proposed-public-offering-common-stock-0 2020-02-12T21:14:45-05:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-announces-us-food-and-drug-administration-acceptance-new-drug 2020-02-12T21:01:44-05:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-provides-corporate-update-and-highlights-key-2020-milestones 2020-01-13T14:00:40-05:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-present-38th-annual-jp-morgan-healthcare-conference 2020-01-06T12:00:41-05:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-announces-submission-new-drug-application-us-fda-ripretinib-patients 2019-12-16T12:00:42-05:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-announces-appointment-ron-squarer-its-board-directors 2019-12-04T21:05:32-05:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-expands-its-board-directors-appointment-frank-s-friedman 2019-11-26T12:00:46-05:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-inc-present-data-dcc-3014-and-ripretinib-programs-connective-tissue 2019-11-13T21:30:38-05:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-inc-present-upcoming-investor-conferences-1 2019-11-13T12:00:36-05:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-inc-announces-third-quarter-2019-financial-results 2019-11-04T21:03:26-05:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-presents-updated-data-ripretinib-and-dcc-3014-programs-aacr-nci 2019-10-29T16:30:42-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-presents-data-rebastinib-and-dcc-3116-programs-aacr-nci-eortc 2019-10-28T16:30:34-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-inc-announce-third-quarter-2019-financial-results-and-host 2019-10-28T11:00:35-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-present-data-updates-portfolio-kinase-switch-control-inhibitors-four 2019-10-16T20:57:50-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-appoints-matthew-l-sherman-md-executive-vice-president-and-chief 2019-10-02T11:00:34-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-announces-late-breaking-oral-presentation-esmo-2019-congress 2019-09-30T13:06:33-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-inc-present-2019-cantor-global-healthcare-conference 2019-09-25T11:00:48-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-announces-late-breaking-oral-presentation-pivotal-phase-3-invictus 2019-09-05T11:00:59-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-announces-full-exercise-underwriters-option-purchase-additional 2019-09-03T20:01:39-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-announces-closing-public-offering-common-stock-0 2019-08-19T20:01:30-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-announces-pricing-public-offering-common-stock-1 2019-08-15T02:43:43-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-announces-proposed-public-offering-common-stock-1 2019-08-13T20:01:35-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-reports-positive-updated-phase-1-data-ripretinib-gastrointestinal 2019-08-13T11:45:17-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-announces-positive-top-line-results-invictus-pivotal-phase-3 2019-08-13T11:46:05-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-inc-announces-second-quarter-2019-financial-results 2019-08-02T11:00:34-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-inc-announces-appointment-susan-l-kelley-md-its-board-directors 2019-07-08T20:05:44-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-inc-and-zai-lab-limited-announce-exclusive-license-agreement 2019-06-11T11:00:53-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-inc-expands-pipeline-potential-first-class-autophagy-inhibitor-treat 2019-06-10T11:00:38-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-inc-present-jefferies-global-healthcare-conference 2019-05-30T11:00:42-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-inc-present-ubs-global-healthcare-conference 2019-05-14T20:05:37-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-inc-announces-first-quarter-2019-financial-results 2019-05-09T20:05:31-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-inc-announces-fourth-quarter-and-year-end-2018-financial-results 2019-03-14T20:05:57-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-inc-announces-retirement-michael-d-taylor-phd 2019-03-04T21:09:19-05:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-inc-present-1st-annual-guggenheim-healthcare-talks-idea-forum 2019-02-07T12:00:57-05:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-initiates-phase-1b2-clinical-trial-rebastinib-combination 2019-01-03T12:32:42-05:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-announces-positive-preliminary-top-line-clinical-data-ongoing-phase 2019-01-02T12:31:19-05:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-inc-present-37th-annual-jp-morgan-healthcare-conference 2019-01-02T12:04:21-05:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-initiates-pivotal-phase-3-clinical-study-ripretinib-dcc-2618-second 2018-12-20T12:04:38-05:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-inc-present-30th-annual-piper-jaffray-healthcare-conference 2018-11-20T12:01:43-05:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-completes-enrollment-invictus-pivotal-phase-3-clinical-study-dcc 2018-11-15T21:23:03-05:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-inc-announces-third-quarter-2018-financial-results 2018-11-08T12:03:56-05:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-initiates-phase-1b2-clinical-trial-rebastinib-combination-paclitaxel 2018-10-23T11:02:18-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-reports-updated-preliminary-phase-1-clinical-study-results-dcc-2618 2018-10-19T12:03:55-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-inc-present-2018-cantor-global-healthcare-conference 2018-09-25T11:01:35-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-appoints-daniel-c-martin-chief-commercial-officer 2018-09-18T11:31:55-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-inc-participate-citis-13th-annual-biotech-conference 2018-08-29T11:02:59-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-inc-announces-second-quarter-2018-financial-results 2018-08-07T20:07:35-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-inc-present-38th-annual-canaccord-genuity-growth-conference 2018-08-01T11:02:31-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-announces-full-exercise-underwriters-option-purchase-additional-0 2018-06-20T20:07:01-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-inc-present-jmp-securities-2018-life-sciences-conference 2018-06-13T11:02:23-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-announces-closing-public-offering-common-stock-1 2018-06-11T22:23:51-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-announces-pricing-public-offering 2018-06-07T02:33:06-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-announces-proposed-public-offering-common-stock-2 2018-06-04T20:14:16-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-reports-updated-interim-phase-1-clinical-study-results-dcc-2618-2018 2018-06-02T13:32:14-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-appoints-stephen-b-ruddy-phd-chief-technical-officer 2018-05-29T12:33:48-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-expands-board-election-mr-steven-l-hoerter-director 2018-05-21T12:33:55-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-inc-present-upcoming-investor-conferences-2 2018-05-14T11:02:42-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-inc-announces-first-quarter-2018-financial-results 2018-05-08T20:07:42-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-inc-report-clinical-data-dcc-2618-upcoming-2018-american-society 2018-04-25T20:04:06-04:00 0.5 https://www.deciphera.com/news/preclinical-data-demonstrate-deciphera-pharmaceuticals-dcc-2618-exhibits-broader-inhibition 2018-04-17T13:03:08-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-inc-reports-updated-data-ongoing-phase-1-clinical-trial-dcc-2618 2018-04-16T12:03:45-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-inc-announces-fourth-quarter-2017-financial-results-and-corporate 2018-03-28T20:02:40-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-inc-report-clinical-and-preclinical-data-dcc-2618-upcoming-2018 2018-03-15T12:31:26-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-initiates-phase-3-clinical-study-dcc-2618-patients-advanced 2018-02-14T18:31:17-05:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-inc-present-36th-annual-jp-morgan-healthcare-conference 2018-01-03T12:02:06-05:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-inc-added-russell-2000r-index 2017-12-18T12:02:59-05:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-inc-announces-orphan-drug-designation-ema-dcc-2618-treatment 2017-11-28T12:03:53-05:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-inc-present-29th-annual-piper-jaffray-healthcare-conference 2017-11-21T12:02:51-05:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-reports-data-ongoing-phase-1-clinical-study-dcc-2618-22nd-annual 2017-11-20T12:03:42-05:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-inc-announces-third-quarter-2017-financial-results-and-corporate 2017-11-14T12:03:59-05:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-inc-reports-data-analysis-ongoing-phase-1-clinical-trial-dcc-2618 2017-11-10T17:51:33-05:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-inc-report-clinical-data-dcc-2618-upcoming-22nd-annual-scientific 2017-11-06T13:19:28-05:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-announces-closing-initial-public-offering-and-exercise-option 2017-10-03T11:39:50-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-announces-pricing-initial-public-offering 2017-09-28T14:04:48-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-reports-updated-data-ongoing-phase-1-clinical-study-dcc-2618 2017-09-12T19:16:48-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-announces-fda-orphan-drug-designation-dcc-2618-treatment 2017-09-08T16:51:24-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-present-updated-data-ongoing-phase-1-study-dcc-2618-2017-european 2017-09-08T18:32:59-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-reports-updated-phase-1-clinical-study-results-dcc-2618-2017 2017-09-08T18:35:34-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-announces-52-million-series-c-financing-advance-novel-clinical-stage 2017-09-12T19:21:49-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-report-phase-1-clinical-study-results-dcc-2618-2017-american-society 2017-09-12T19:24:26-04:00 0.5 https://www.deciphera.com/news/translational-research-results-confirm-broad-activity-dcc-2618-gist-patients-difficult-treat 2017-09-13T15:41:03-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-present-27th-annual-oppenheimer-healthcare-conference 2017-09-13T15:43:09-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-report-translational-research-findings-dcc-2618-2017-american 2017-09-13T15:44:29-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-initiates-phase-1-clinical-trial-dcc-3014 2017-09-13T15:45:38-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-present-35th-annual-jp-morgan-healthcare-conference 2017-09-13T15:46:32-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-reports-encouraging-clinical-results-dcc-2618-genetically-defined 2017-09-13T15:50:31-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-present-clinical-data-tumor-targeted-advanced-kinase-inhibitors-28th 2017-09-13T15:52:03-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-expands-board-appointment-two-new-directors 2017-09-13T15:57:28-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-appoints-christopher-j-morl-mba-chief-business-officer 2017-09-13T15:55:04-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-present-canaccord-genuity-36th-annual-growth-conference 2017-09-13T16:01:09-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-present-jmp-securities-life-sciences-conference-0 2017-09-13T16:24:59-04:00 0.5 https://www.deciphera.com/news/decipheras-highly-selective-small-molecule-csf1r-immunokinase-inhibitor-dcc-3014-demonstrates 2017-09-13T16:28:37-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-announces-study-results-altiratinib-demonstrating-inhibition-tumor 2017-09-13T16:32:31-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-present-data-its-highly-selective-small-molecule-csf1r-immunokinase 2017-09-13T16:35:18-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-present-american-chemical-society-annual-meeting 2017-09-13T16:38:59-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-present-future-leaders-biotech-industry-conference 2017-09-13T16:41:12-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-increases-size-series-b-financing-over-90-million-addition-sv-life 2017-09-13T16:46:20-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-present-oppenheimer-annual-healthcare-conference 2017-09-13T16:53:25-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-present-piper-jaffray-healthcare-conference 2017-09-13T17:03:08-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-announces-75-million-series-b-financing-advance-novel-oncology 2017-09-13T17:04:37-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-announces-study-results-altiratinib-demonstrating-inhibition-three 2017-09-13T17:06:35-04:00 0.5 https://www.deciphera.com/news/top-medical-oncologists-join-deciphera-pharmaceuticals-scientific-advisory-board 2017-09-13T17:08:21-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-present-jmp-securities-life-sciences-conference-1 2017-09-13T17:09:50-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-presents-data-highlighting-kinase-inhibitor-pipeline-including 2017-09-13T17:11:23-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-present-14th-annual-needham-healthcare-conference 2017-09-13T17:13:07-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-present-jmp-securities-life-sciences-private-company-conference 2017-09-13T17:14:43-04:00 0.5 https://www.deciphera.com/news/deciphera-present-data-oncology-pipeline-american-association-cancer-research-annual-meeting 2017-09-13T17:16:23-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-present-future-leaders-biotech-industry-conference-0 2017-09-13T17:21:36-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-appoints-tucker-kelly-chief-financial-officer 2017-09-13T17:22:49-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-presents-data-altiratinib-dcc-2701-advanced-multi-targeted-kinase 2017-09-13T19:19:38-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-presents-data-altiratinib-dcc-2701-demonstrated-inhibition-tumor 2017-09-13T19:21:15-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-appoints-oliver-rosen-md-chief-medical-officer 2017-09-13T19:22:54-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-announces-initiation-phase-1-cancer-trial-altiratinib-dcc-2701 2017-09-13T19:46:54-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-announces-initiation-phase-1-cancer-trial-ly3009120-pan-raf 2017-09-13T19:26:05-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-appoints-michael-d-taylor-phd-president-and-chief-executive-officer 2017-09-13T19:27:39-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-presents-preclinical-data-rebastinib-and-dcc-3014-aacr-tumor 2017-09-13T19:29:52-04:00 0.5 https://www.deciphera.com/news/deciphera-announces-appointment-john-de-groot-md-its-scientific-advisory-board 2017-09-13T19:43:30-04:00 0.5 https://www.deciphera.com/news/deciphera-announces-appointment-john-condeelis-its-scientific-advisory-board 2017-09-13T19:44:55-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-announces-transition-oncology-drug-development-company 2017-09-13T19:46:25-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-announces-approval-rebastinib-patent-japan 2017-09-13T19:48:38-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmacueticals-announces-appointment-kapil-bhalla-md-its-scientific-advisory-board 2017-09-13T19:50:34-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-announces-appointment-dr-patrick-oconnor-its-scientific-advisory 2017-09-13T19:52:08-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-announces-collaboration-milestone-eli-lilly-and-company 2017-09-13T19:53:19-04:00 0.5 https://www.deciphera.com/news/kansas-biosciences-authority-votes-favor-16mm-product-development-grant-deciphera 2017-09-13T19:54:33-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-and-university-kansas-cancer-center-team-clinical-study-leukemia 2017-09-13T19:56:20-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-announces-dcc-2036-research-cml-published-cancer-cell 2017-09-13T19:57:57-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-announces-extension-braf-collaboration-and-receipt-development 2017-09-13T19:59:23-04:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-announces-initiation-dcc-2036-phase-1-clinical-trial-refractory-cml 2017-09-13T20:00:38-04:00 0.5 https://www.deciphera.com/news/ku-lease-out-vacant-lab-space-local-expansion-deciphera-pharmaceuticals 2017-09-13T20:02:22-04:00 0.5 https://www.deciphera.com/news/lilly-and-deciphera-pharmaceuticals-announce-licensing-and-collaboration-agreement 2017-09-13T20:03:41-04:00 0.5 https://www.deciphera.com/news/european-medicines-agency-accepts-decipheras-marketing-authorization-application-vimseltinib 2024-07-18T20:00:00-04:00 0.5 https://www.deciphera.com/news/us-food-and-drug-administration-accepts-priority-review-decipheras-new-drug-application 2025-03-13T12:26:19-04:00 0.5 https://www.deciphera.com/news/us-fda-grants-full-approval-decipheras-romvimzatm-vimseltinib-treatment-symptomatic 2025-02-18T08:50:33-05:00 0.5 https://www.deciphera.com/news/ono-pharmaceutical-announces-reorganization-its-us-and-europe-operations 2025-02-28T16:00:10-05:00 0.5 https://www.deciphera.com/news/ono-enters-license-agreement-ionis-pharmaceuticals-sapablursen-treatment-polycythemia-vera 2025-03-11T18:30:29-04:00 0.5 https://www.deciphera.com/news/ono-commences-research-collaboration-jorna-therapeutics-generate-novel-rna-editing 2025-04-21T10:27:05-04:00 0.5 https://www.deciphera.com/news/ono-achieves-top-1-sp-sustainability-yearbook-2025 2025-04-21T11:03:22-04:00 0.5 https://www.deciphera.com/news/ono-pharma-announces-oral-presentation-phase-2-data-tirabrutinib-and-poster-session-ono-4578 2025-04-23T20:20:10-04:00 0.5 https://www.deciphera.com/news/ono-pharma-presents-positive-results-pivotal-trial-us-patients-relapsed-or-refractory-pcnsl-0 2025-05-28T10:08:46-04:00 0.5 https://www.deciphera.com/news/deciphera-announces-positive-chmp-opinion-romvimzatm-vimseltinib-treatment-tenosynovial-giant 2025-07-28T09:30:48-04:00 0.5 https://www.deciphera.com/news/deciphera-receives-european-commission-approval-for-romvimza 2025-09-17T16:30:19-04:00 0.5 https://www.deciphera.com/news/deciphera-presents-2-year-efficacy-and-safety-results-motion-phase-3-study-romvimzatm 2025-10-18T07:49:46-04:00 0.5 https://www.deciphera.com/news/deciphera-announces-multiple-data-presentations-connective-tissue-oncology-society-ctos-annual 2025-11-12T09:39:56-05:00 0.5 https://www.deciphera.com/news/deciphera-announces-oral-presentation-positive-topline-results-phase-2a-study-sapablursen 2026-02-17T07:11:00-05:00 0.5 https://www.deciphera.com/news/deciphera-pharmaceuticals-announces-us-food-and-drug-administration-acceptance-filing-new-drug 2026-02-17T13:24:02-05:00 0.5 https://www.deciphera.com/news/ono-pharma-submits-application-approval-ripretinib-dcc-2618-patients-advanced-gastrointestinal 2026-03-26T00:43:00-04:00 0.5 https://www.deciphera.com/leadership/daniel-l-flynn-phd 2021-04-05T14:55:37-04:00 0.5 https://www.deciphera.com/leadership/caroline-chevalier 2021-03-17T19:05:10-04:00 0.5 https://www.deciphera.com/leadership/daniel-c-martin 2021-03-17T19:17:27-04:00 0.5 https://www.deciphera.com/leadership/stephen-b-ruddy-phd 2021-03-17T19:22:10-04:00 0.5 https://www.deciphera.com/leadership/matthew-l-sherman-md 2026-03-17T15:17:44-04:00 0.5 https://www.deciphera.com/leadership/rodrigo-ruiz-soto-md 2021-06-29T10:45:19-04:00 0.5 https://www.deciphera.com/leadership/james-bristol-phd 2023-11-03T14:04:45-04:00 0.5 https://www.deciphera.com/leadership/patricia-l-allen 2023-01-05T13:04:36-05:00 0.5 https://www.deciphera.com/leadership/edward-j-benz-jr-md 2021-08-04T15:59:39-04:00 0.5 https://www.deciphera.com/leadership/frank-s-friedman 2021-04-06T10:51:19-04:00 0.5 https://www.deciphera.com/leadership/susan-l-kelley-md 2022-02-01T16:56:25-05:00 0.5 https://www.deciphera.com/leadership/john-r-martin 2022-04-18T18:45:59-04:00 0.5 https://www.deciphera.com/leadership/ron-squarer 2023-08-06T01:52:13-04:00 0.5 https://www.deciphera.com/leadership/dennis-l-walsh 2022-04-18T18:47:44-04:00 0.5 https://www.deciphera.com/leadership/jenn-larson-cpa 2026-03-17T15:17:09-04:00 0.5 https://www.deciphera.com/leadership/maria-ostrovsky 2026-03-17T15:17:26-04:00 0.5 https://www.deciphera.com/leadership/peter-habura 2026-03-17T15:16:41-04:00 0.5 https://www.deciphera.com/leadership/ryota-udagawa 2026-03-17T15:15:41-04:00 0.5 https://www.deciphera.com/pipeline 2025-11-18T12:31:27-05:00 0.5 https://www.deciphera.com/pipeline/ripretinib 2025-11-18T11:37:35-05:00 0.5 https://www.deciphera.com/pipeline/vimseltinib 2025-11-18T11:38:18-05:00 0.5 https://www.deciphera.com/pipeline/inlexisertib 2025-11-18T11:53:54-05:00 0.5 https://www.deciphera.com/pipeline/dcc-2812 2025-11-18T11:31:57-05:00 0.5 https://www.deciphera.com/dcc-3084 2025-04-08T16:12:05-04:00 0.5 https://www.deciphera.com/pipeline/dcc-3009 2026-01-06T10:13:56-05:00 0.5 https://www.deciphera.com/tirabrutinib 2025-11-18T11:23:39-05:00 0.5 https://www.deciphera.com/sapablursen 2025-11-18T11:25:18-05:00 0.5 https://www.deciphera.com/ono-4578 2025-11-18T11:28:04-05:00 0.5 https://www.deciphera.com/ono-2808 2025-11-20T11:44:58-05:00 0.5 https://www.deciphera.com/ono-2020 2025-11-18T11:29:46-05:00 0.5 https://www.deciphera.com/ono-4685 2025-11-18T11:30:59-05:00 0.5